SOURCE: The Bedford Report

The Bedford Report

May 26, 2011 08:16 ET

Investors Hopeful for Blockbusters From BioSante and Sunesis

The Bedford Report Provides Analyst Research on BioSante and Sunesis

NEW YORK, NY--(Marketwire - May 26, 2011) - Recent studies have shown that the chances of FDA approval for early stage drugs is dropping significantly. Although it remains an exciting time in the biotech sector with several potential blockbusters working their way through the regulatory process, now, more than ever, many analysts are urging investors to use caution. The Bedford Report examines the outlook for companies in the Biotechnology Industry and provides research reports on BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) and Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS). Access to the full company reports can be found at:

www.bedfordreport.com/2011-05-BPAX
www.bedfordreport.com/2011-05-SNSS

A study released by BIO and BioMedTracker claims that the success rate in bringing new medicines to market in the past six years is only about half of what it had been previously. The study claims, however that biotech drugs are twice as likely to gain approval, compared to more traditional chemical drugs.

The importance of maintaining a steady pipeline of drugs to market is having varied effects on the biotechnology industry. Larger firms are leaning on acquisitions to quickly expand their product lines while smaller ones are opting for increased spending on research and development. This creates two potential avenues of profit for speculative biotech investors: a greater chance of a blockbuster drug or being acquired by a larger firm eager to boost its pipeline.

The Bedford Report releases regular market updates on the Healthcare Sector so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.bedfordreport.com and get exclusive access to our numerous analyst reports and industry newsletters.

BioSante is a pharmaceutical company focused on developing products for female sexual health and oncology. In the most recent quarter the company posted a wider loss on higher development costs for its drug candidate "LibiGel." LibiGel is in late-stage clinical trials and is intended to treat sexual dysfunction in women.

Sunesis Pharmaceuticals' most advanced drug candidate is Vosaroxin, which is being studied as a treatment for acute myeloid leukemia that has recurred or not responded to previous treatment. The Food and Drug Administration awarded the drug "fast-track" status earlier this year.

The Bedford Report provides Analyst Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned publicly traded companies. The Bedford Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.bedfordreport.com/disclaimer

Contact Information